Literature DB >> 27012849

Differential T-cell responses to a chimeric Plasmodium falciparum antigen; UB05-09, correlates with acquired immunity to malaria.

J N Dinga1, D L Njimoh1, B Kiawa2, A Djikeng2, R B Nyasa3, T Nkuo-Akenji3, R Pellé2, V P K Titanji1,4.   

Abstract

The development of a sterilizing and cost-effective vaccine against malaria remains a major problem despite recent advances. In this study, it is demonstrated that two antigens of P. falciparum UB05, UB09 and their chimera UB05-09 can serve as protective immunity markers by eliciting higher T-cell responses in malaria semi-immune subjects (SIS) than in frequently sick subjects (FSS) and could be used to distinguish these two groups. UB05, UB09 and UB05-09 were cloned, expressed in E. coli, purified and used to stimulate PBMCs isolated from 63 subjects in a malaria endemic area, for IFN-γ production, which was measured by the ELISpot assay. The polymorphism of UB09 gene in the malaria infected population was also studied by PCR/sequencing of the gene in P. falciparum field isolates. All three antigens were preferentially recognized by PBMCs from SIS. IFN-γ production induced by these antigens correlated with the absence of fever and parasitaemia. UB09 was shown to be relatively well-conserved in nature. It is concluded that UB05, UB09 and the chimera UB05-09 posses T-cell epitopes that are associated with protection against malaria and could thus be used to distinguish SIS from FSS eventhough acute infection with malaria has been shown to reduce cytokine production in some studies. Further investigations of these antigens as potential diagnostic and/or vaccine candidates for malaria are indicated.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  ELISpot; Plasmodium falciparum; T-cell epitopes; UB05; UB05-09; UB09; malaria; subunit vaccine

Mesh:

Substances:

Year:  2016        PMID: 27012849     DOI: 10.1111/pim.12318

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  3 in total

1.  Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.

Authors:  J N Dinga; S D Gamua; S M Ghogomu; V P K Titanji
Journal:  Parasite Immunol       Date:  2018-01-25       Impact factor: 2.280

2.  Enhanced acquired antibodies to a chimeric Plasmodium falciparum antigen; UB05-09 is associated with protective immunity against malaria.

Authors:  J N Dinga; S D Gamua; V P K Titanji
Journal:  Parasite Immunol       Date:  2017-06-22       Impact factor: 2.280

3.  Analysis of the Role of TpUB05 Antigen from Theileria parva in Immune Responses to Malaria in Humans Compared to Its Homologue in Plasmodium falciparum the UB05 Antigen.

Authors:  Jerome Nyhalah Dinga; Stephanie Numenyi Perimbie; Stanley Dobgima Gamua; Francis N G Chuma; Dieudonné Lemuh Njimoh; Appolinaire Djikeng; Roger Pelle; Vincent P K Titanji
Journal:  Pathogens       Date:  2020-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.